Revenue - Clovis Oncology Inc (NASDAQ:CLVS) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 0.093 USD 3.33%

Updated:

Clovis Oncology Inc
Revenue

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

|

Adjust for Inflation

Clovis Oncology Inc
Revenue Peer Comparison

ABBV

GILD

AMGN

VRTX

REGN

Company		Revenue	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Clovis Oncology Inc NASDAQ:CLVS	Revenue $148.8m	CAGR 3-Years 16%	CAGR 5-Years 331%	CAGR 10-Years N/A
	Abbvie Inc NYSE:ABBV	Revenue $54.3B	CAGR 3-Years 6%	CAGR 5-Years 11%	CAGR 10-Years 11%
	Gilead Sciences Inc NASDAQ:GILD	Revenue $27.5B	CAGR 3-Years 2%	CAGR 5-Years 4%	CAGR 10-Years 7%
	Amgen Inc NASDAQ:AMGN	Revenue $28.2B	CAGR 3-Years 4%	CAGR 5-Years 3%	CAGR 10-Years 4%
	Vertex Pharmaceuticals Inc NASDAQ:VRTX	Revenue $9.9B	CAGR 3-Years 17%	CAGR 5-Years 26%	CAGR 10-Years 23%
	Regeneron Pharmaceuticals Inc NASDAQ:REGN	Revenue $13.1B	CAGR 3-Years 16%	CAGR 5-Years 14%	CAGR 10-Years 20%

Clovis Oncology Inc
Revenue Breakdown

Total Revenue: 148.8m USD

100%

115.7m USD

77.8%

33.1m USD

22.2%

See Also

Based on the financial report for Dec 31, 2021, Clovis Oncology Inc's Revenue amounts to 148.8m USD.

Over the last year, the Revenue growth was -10%. The average annual Revenue growth rates for Clovis Oncology Inc have been 16% over the past three years , 331% over the past five years .

Join more than 134,000+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.